| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14656566.2017.1363178 |
| P698 | PubMed publication ID | 28780896 |
| P2093 | author name string | A John Rush | |
| Joseph F Goldberg | |||
| P2860 | cites work | Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys | Q28279105 |
| Data-Driven Phenotypic Categorization for Neurobiological Analyses: Beyond DSM-5 Labels | Q31133061 | ||
| Poor replication of candidate genes for major depressive disorder using genome-wide association data | Q33547331 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression | Q34337526 | ||
| Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. | Q34452500 | ||
| Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder | Q34462756 | ||
| Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group | Q34514128 | ||
| A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents | Q34568810 | ||
| Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report | Q34658729 | ||
| The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry | Q34660881 | ||
| Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium | Q37603806 | ||
| Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study | Q37644483 | ||
| Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial | Q37725117 | ||
| Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial. | Q38391263 | ||
| Does refining the phenotype improve replication rates? A review and replication of candidate gene studies on Major Depressive Disorder and Chronic Major Depressive Disorder | Q38633011 | ||
| Precision medicine for psychopharmacology: a general introduction | Q38814860 | ||
| Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder | Q40327886 | ||
| The $2.6 billion pill--methodologic and policy considerations | Q40944246 | ||
| Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials | Q42164457 | ||
| Pharmacogenetic Tests in Psychiatry: From Fear to Failure to Hype | Q42696331 | ||
| A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression | Q43598189 | ||
| Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report | Q44216146 | ||
| Rethinking funding priorities in mental health research | Q45035305 | ||
| Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome | Q46262574 | ||
| Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment | Q47368013 | ||
| A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder | Q47710967 | ||
| An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline | Q48255615 | ||
| Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 | ||
| Is pharma running out of brainy ideas? | Q51847289 | ||
| Ketamine – More mechanisms of action than just NMDA blockade | Q56050279 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1417-1420 | |
| P577 | publication date | 2017-08-07 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research? | |
| P478 | volume | 18 |
Search more.